HSP90 inhibition: two-pronged exploitation of cancer dependencies.

  title={HSP90 inhibition: two-pronged exploitation of cancer dependencies.},
  author={Jon Travers and Swee Sharp and Paul Workman},
  journal={Drug discovery today},
  volume={17 5-6},
The early clinical hypothesis for inhibiting HSP90 in cancers was based on the dependence of certain key client proteins in malignant cells--including a host of well-characterized oncoproteins--on the activity of HSP90 for their function and stability. The additional concept has been established that cancer cells have heightened dependence on the efficient maintenance of intracellular proteomic homeostasis, central components of which are HSP90 and other heat shock proteins. We evaluate the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 46 extracted citations

HSP90: Chaperone-me-not

Pathology & Oncology Research • 2013
View 11 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 97 references

A Phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas

A Rajan
Clin. Cancer Res • 2011

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

S Pacey
Clin . Cancer Res . • 2011

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

K Jhaveri

Similar Papers

Loading similar papers…